Ascentage Pharma Group Inc.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Ascentage Pharma Group Inc.
RECRUITINGPhase 1NCT04275518
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature,...
Sponsor: Ascentage Pharma Group Inc.Enrolling: 10214 locations
Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
RECRUITINGPhase 1NCT03917043
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449...
Sponsor: Ascentage Pharma Group Inc.Enrolling: 1659 locations
Advanced Solid CancerNon Small Cell Lung CancerEsophageal Cancer+2